Dan Barber

Dan Barber, President and CEO of Equestive Therapeutics, dives into the groundbreaking oral thin-film epinephrine product, Anafilm. He shares insights on its FDA fast-track status and the potential to transform anaphylaxis treatment by significantly increasing prescriptions. Barber discusses the size of the current epinephrine market and anticipates expansion in adoption. He also reveals Equestive's innovative Adreniverse platform, paving the way for future advancements in various indications.